24 results on '"Yuehui Lin"'
Search Results
2. Efficacy and safety of high-dose intramuscular vitamin D2 injection in type 2 diabetes mellitus with distal symmetric polyneuropathy combined with vitamin D insufficiency: study protocol for a multicenter, randomized, double-blinded, and placebo-controlled trial
- Author
-
Tao Chen, Xiaoyan Xing, Lihua Huang, Mei Tu, Xiaoli Lai, Shidi Wen, Jin Cai, Shenglong Lin, Youping Zheng, Yuehui Lin, Lijuan Xu, Yuwen Qiu, Lumin Qiu, Yuebo Xu, and Peiwen Wu
- Subjects
type 2 diabetes mellitus ,distal symmetric polyneuropathy ,high-dose vitamin D supplementation ,Michigan neuropathy screening instrument ,randomized controlled trial ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
BackgroundDistal symmetric polyneuropathy (DSPN) is the most common chronic complication of type 2 diabetes mellitus (T2DM). DSPN may lead to more serious complications, such as diabetic foot ulcer, amputation, and reduced life expectancy. Observational studies have suggested that vitamin D deficiency may be associated with the development of DSPN in T2DM. However, interventional studies have found that low-dose vitamin D supplementation does not significantly improve neuropathy in DSPN. This study aims to evaluate the efficacy and safety of intramuscular injection of high-dose vitamin D (HDVD) in T2DM with DSPN combined with vitamin D insufficiency.Methods and analysisWe will conduct a multicenter, randomized, double-blinded, and placebo-controlled trial in four large hospitals. All eligible participants will be randomly assigned to either the vitamin D2 supplement or placebo control group and injected intramuscularly monthly for 3 months. Additionally, anthropometric measurements and clinical data will be collected at baseline and 3 months. Adverse events will be collected at 1, 2, and 3 months. The primary outcome measure is the change in the mean Michigan Neuropathy Screening Instrument (MNSI) score at baseline and 3 months post-intervention. We will use the gold-standard liquid chromatography-tandem mass spectrometry method to distinguish between 25(OH)D2 and 25(OH)D3 levels. The MNSN score before the intervention will be used as a covariate to compare the changes between both groups before and after the intervention, and the analysis of covariance will be used to analyze the change in the MNSI score after HDVD supplementation.DiscussionGlycemic control alone does not prevent the progression of DSPN in T2DM. Some studies have suggested that vitamin D may improve DSPN; however, the exact dose, method, and duration of vitamin D supplementation are unknown. Additionally, neuropathy repair requires HDVD supplementation to sustain adequate vitamin D levels. This once-a-month intramuscular method avoids daily medication; therefore, compliance is high. This study will be the first randomized controlled trial in China to analyze the efficacy and safety of HDVD supplementation for patients with T2DM and DSPN and will provide new ideas for pharmacological research and clinical treatment of diabetic neuropathy.Clinical trial registrationhttps://www.chictr.org.cn/, identifier ChiCTR2200062266.
- Published
- 2023
- Full Text
- View/download PDF
3. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
- Author
-
Lihong An, Yuehui Lin, Biping Deng, Zhichao Yin, Defeng Zhao, Zhuojun Ling, Tong Wu, Yongqiang Zhao, Alex H. Chang, Chunrong Tong, and Shuangyou Liu
- Subjects
Chimeric antigen receptor-T ,Acute lymphoblastic leukemia ,Relapsed/refractory ,Single-chain variable fragment ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background For CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) after treatment with murine CD19 (mCD19) CAR-T, the reinfusion of mCD19 CAR-T cells may be ineffective due to anti-mouse single-chain variable fragment (scFv) antibody caused by mCD19 CAR. To overcome this immunogenicity, we applied humanized CD19 (hCD19) CAR-T cells to treat r/r B-ALL patients with prior mCD19 CAR-T therapy. Methods Nineteen pediatric and adult patients were included, 16 relapsed after and 3 were primarily resistant to mCD19 CAR-T. All patients presented with more than 5% blasts in bone marrow and/or extramedullary disease, and still showed CD19 antigen expression. Humanized CD19-CARs were lentiviral vectors carrying a second generation CAR with 4–1-BB co-stimulatory and CD3ζ signaling domains. Patient-derived cells were collected for producing CAR-T cells, the median dose of infused hCD19 CAR-T cells was 2.4 × 105/kg (range, 1.0–18.0 × 105/kg). Results hCD19 CAR-T resulted in a complete remission (CR) rate of 68% (13/19). Among 13 remission patients, 11 underwent allogeneic hematopoietic cell transplantation (allo-HCT) (3 were second HCT) and 10 remained in CR; the event-free survival rates at 12–18 months were 91% in 11 patients received following allo-HCT and 69% in all CR patients. Six cases had no response to hCD19 CAR-T, 3 died of disease progression; another 3 received salvage second transplantation, of them, 2 relapsed again (one died). Cytokine release syndrome (CRS) occurred in 95% (18/19) of patients, most CRS events were grade 1 and grade 2 (n = 17), there was only one grade 4 CRS. Two cases experienced grade 1 neurotoxicity. Conclusions Humanized CD19 CAR-T cell therapy could be a treatment option for CD19-positive B-ALL patients who relapsed after or resisted prior murine CD19 CAR-T, hCD19 CAR-T followed by allo-HCT provided a longer remission in CR patients. Nevertheless, the prognosis of non-responders to hCD19 CAR-T remained dismal. Trial registration Chinese Clinical Trial Registry/WHO International Clinical Trial Registry ( ChiCTR1900024456 , URL: www.chictr.org.cn ); registered on July 12, 2019.
- Published
- 2022
- Full Text
- View/download PDF
4. Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL
- Author
-
Biping Deng, Jing Pan, Zhaoli Liu, Shuangyou Liu, Yunlong Chen, Xiaomin Qu, Yu'e Zhang, Yuehui Lin, Yanlei Zhang, Xinjian Yu, Zhongxin Zhang, Xuansha Niu, Rong Luan, Ming Ma, Xiaomei Li, Tingting Liu, Xi'ai Wu, Huan Niu, Alex H. Chang, and Chunrong Tong
- Subjects
CAR-T cells ,CART19 ,B-cell acute lymphoblastic leukemia ,PB blasts ,leukemia burden in peripheral blood ,time of apheresis ,Genetics ,QH426-470 ,Cytology ,QH573-671 - Abstract
Our previous clinical study achieved complete remission (CR) rates of >90% following chimeric antigen receptor T cells targeting CD19 (CART19) treatment of refractory/relapsed B cell acute lymphoblastic leukemia (r/r B-ALL); however, the influence of the leukemia burden in peripheral blood (PB) blasts remains unclear. Here, we retrospectively analyzed 143 patients treated with CART19 (including 36 patients with PB blasts) to evaluate the effect of peripheral leukemia burden at the time of apheresis. One hundred seventeen patients with high disease burdens achieved 91.5% CR or incomplete count recovery CR and 86.3% minimal residual disease-negative CR, and 26 patients with low disease burdens obtained 96.2% MRD− CR. Collectively, 9 of 36 (25%) patients with PB blasts and 2 of 107 (1.87%) patients without PB blasts did not respond to CART19 therapy. The leukemia burden in PB negatively influenced ex vivo cell characteristics, including the transduction efficiency of CD3+ T cells and their fold expansion, and in vivo cell dynamics, including peak CART19 proportion and absolute count, fold expansion, and persistence duration. Further studies showed that these patients had higher programmed death-1 expression in CART19 products. Our data imply that PB blasts negatively affected CART19 production and the clinical efficacy of CART19 therapy in patients with r/r B-ALL.
- Published
- 2021
- Full Text
- View/download PDF
5. CAR‐T therapy as a consolidation in remission B‐ALL patients with poor prognosis
- Author
-
Zhichao Yin, Yuehui Lin, Dan Liu, Chunrong Tong, and Shuangyou Liu
- Subjects
B‐cell acute lymphoblastic leukemia ,CAR T‐cells ,complete remission ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background To date, almost all studies regarding chimeric antigen receptor (CAR)‐T cell therapy for B‐cell acute lymphoblastic leukemia (B‐ALL) were performed in refractory/relapsed (r/r) or minimal residual disease‐positive patients. CAR‐T therapy in remission patients has not been reported. Aim To observe the treatment outcome of CAR‐T cells for remission B‐ALL patients with poor prognosis. Methods and Results CAR‐T treatment was applied to two B‐ALL patients in remission status who had poor prognostic factors and refused transplantation, and one case was unable to accept standard chemotherapy owing to multiple complications. The procedure of CAR‐T therapy in these two remission patients was the same as that in r/r B‐ALL patients. Lentiviral vectors encoding second generation CARs composed of CD3ζ and 4‐1BB were used to produce CAR‐T cells. Lymphodepleting agents fludarabine and cyclophosphamide were administered prior to cell infusion. Grade I cytokine release syndrome occurred after each T‐cell infusion and there was no neurotoxicity. CAR‐T treatment followed by non‐intensive maintenance chemotherapy and targeted drugs allowed both patients to obtain a long‐term event‐free survival of more than three and a half years without transplantation. Conclusions CAR‐T therapy could be used in high‐risk B‐ALL patients as a consolidation to avoid transplantation, the combination of CAR‐T and following maintenance therapy may be better than CAR‐T alone for durable remission.
- Published
- 2022
- Full Text
- View/download PDF
6. Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy
- Author
-
Jingjing Deng, Yuehui Lin, Defeng Zhao, Chunrong Tong, Alex H. Chang, Wenming Chen, and Wen Gao
- Subjects
plasma cell leukemia ,relapsed/refractory multiple myeloma ,chimeric antigen receptor T cell therapy ,secondary plasma cell leukemia ,treatment ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Chimeric antigen receptor (CAR)-T cell therapy provides an effective salvage treatment for relapsed/refractory multiple myeloma (RRMM) patients. End-stage RRMM with plasma cell leukemia (PCL) transformation is highly aggressive and resistant to conventional therapy. There is an urgent need for new therapeutics and CAR-T therapy may play an important role. We report a case of PCL secondary to RRMM successfully treated with CAR-T cell therapy targeting B-cell maturation antigen (BCMA). A woman was diagnosed as having MM 4 years ago and progressed to secondary PCL (sPCL) of five prior lines of treatment including proteasome inhibitors, an immunomodulatory agent, cytotoxic drugs, and an anti-CD38 monoclonal antibody. After receiving a BCMA CAR-T therapy, she achieved a stringent complete response that lasted 9 months. Then, the patient irregularly took venetoclax 10 mg per day due to a slightly higher λ FLC concentration, which did not meet the criteria for progression. She maintained a complete response for the following 7 months. In conclusion, BCMA CAR-T therapy may be a promising therapeutic approach in PCL patients. More studies are needed to evaluate the benefit of anti-BCMA CAR-T therapy in PCL patients.Clinical Trial Registration:www.chictr.org.cn, ChiCTR1900024388, Registered 9 July 2019.
- Published
- 2022
- Full Text
- View/download PDF
7. A study on the formula of fundamental period of high-rise shear wall structures based on ambient vibration testing
- Author
-
Yang, Zhou, Jian, Meng, Yuehui, Lin, Zhengxin, Qi, and Fu, He
- Published
- 2024
- Full Text
- View/download PDF
8. PB1738: OBSERVATION OF THERAPEUTIC EFFECT OF BLINATUMOMAB SALVAGE TREATMENT ON B – ALL WITH INVALID OR RECURRENT CART
- Author
-
Yuehui, Lin, primary
- Published
- 2023
- Full Text
- View/download PDF
9. Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia
- Author
-
Yuehui Lin, Alex H. Chang, Zhuojun Ling, Jing Pan, Zhiyong Gao, Biping Deng, Yongqiang Zhao, Tong Wu, Chunrong Tong, Shuangyou Liu, Zhichao Yin, Dong Chen, and Yanzhi Song
- Subjects
Adult ,Male ,Cancer therapy ,Adolescent ,Kinetics ,Immunotherapy, Adoptive ,lcsh:RC254-282 ,Young Adult ,Adrenal Cortex Hormones ,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ,Correspondence ,Medicine ,Humans ,Child ,Haematological cancer ,business.industry ,Hematology ,B-cell acute lymphoblastic leukemia ,Middle Aged ,Prognosis ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Combined Modality Therapy ,Oncology ,Case-Control Studies ,Child, Preschool ,Cancer research ,Female ,Car t cells ,business ,Follow-Up Studies - Published
- 2020
10. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
- Author
-
Alex H. Chang, Yan Zhang, Tong Wu, Xiaoming Feng, Yongqiang Zhao, Zhichao Yin, Chunrong Tong, Qing Niu, Zhaoli Liu, Jin Gao, Xinjian Yu, Xi-You Tan, Zhiyong Gao, Biping Deng, Jing Pan, Yu’e Zhang, Shaohui Liu, Zhuojun Ling, Xiaomin Qu, Zhihui Li, Yuehui Lin, Yanlei Zhang, Bingzhen Chen, Ju Yan, Qinlong Zheng, Shuangyou Liu, Xuan Zhou, and Yanzhi Song
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Hematology ,Immunotherapy ,Gastroenterology ,Clinical trial ,Transplantation ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,Refractory ,030220 oncology & carcinogenesis ,Internal medicine ,Biopsy ,medicine ,B Acute Lymphoblastic Leukemia ,Young adult ,business ,Survival rate - Abstract
Despite worldwide promising clinical outcome of CD19 CAR-T therapy, relapse after this therapy is associated with poor prognosis and has become an urgent problem to be solved. We conducted a CD22 CAR T-cell therapy in 34 relapsed or refractory (r/r) B-ALL pediatric and adult patients who failed from previous CD19 CAR T-cell therapy. Complete remission (CR) or CR with incomplete count recovery (CRi) was achieved in 24 of 30 patients (80%) that could be evaluated on day 30 after infusion, which accounted for 70.5% of all 34 enrolled patients. Most patients only experienced mild cytokine-release syndrome and neurotoxicity. Seven CR patients received no further treatment, and 3 of them remained in remission at 6, 6.6, and 14 months after infusion. Eleven CR patients were promptly bridged to transplantation, and 8 of them remained in remission at 4.6 to 13.3 months after transplantation, resulted in 1-year leukemia-free survival rate of 71.6% (95% CI, 44.2–99.0). CD22 antigen loss or mutation was not observed to be associated with relapsed patients. Our study demonstrated that our CD22 CAR T-cells was highly effective in inducing remission in r/r B-ALL patients, and also provided a precious window for subsequent transplantation to achieve durable remission.
- Published
- 2019
11. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation
- Author
-
Chunrong Tong, Zhichao Yin, Yuehui Lin, Bingzhen Chen, Biping Deng, Shuangyou Liu, Dan Liu, Tong Wu, Xinjian Yu, Lihong An, Alex H. Chang, and Jing Pan
- Subjects
Male ,CD3 Complex ,medicine.medical_treatment ,Sialic Acid Binding Ig-like Lectin 2 ,Salvage therapy ,Graft vs Host Disease ,Hematopoietic stem cell transplantation ,Kaplan-Meier Estimate ,Gastroenterology ,Immunotherapy, Adoptive ,Cell therapy ,0302 clinical medicine ,immune system diseases ,Recurrence ,hemic and lymphatic diseases ,Child ,Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,Allografts ,Combined Modality Therapy ,Progression-Free Survival ,Treatment Outcome ,030220 oncology & carcinogenesis ,Child, Preschool ,Female ,Cord Blood Stem Cell Transplantation ,Adult ,medicine.medical_specialty ,Allogeneic transplantation ,Adolescent ,Antigens, CD19 ,03 medical and health sciences ,Young Adult ,Antigens, Neoplasm ,Internal medicine ,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ,medicine ,Humans ,Progression-free survival ,Survival analysis ,Salvage Therapy ,business.industry ,Infant ,Immunotherapy ,Transplantation ,4-1BB Ligand ,business ,030215 immunology ,Follow-Up Studies - Abstract
The prognosis of relapsed acute lymphoblastic leukemia (ALL) after allogeneic transplantation is dismal when treated with conventional approaches. While single-target CD19 or CD22 chimeric antigen receptor (CAR) T-cell therapy has achieved high complete remission (CR) rates in refractory/relapsed B-ALL, it could not maintain a durable remission in most patients. To prolong relapse-free survival, we sequentially combined CD19 and CD22 CAR-T cells to treat post-transplant relapsed B-ALL patients with both CD19/CD22 antigen expression on lymphoblasts. Patient-derived donor cells were collected to produce CAR-T cells that were transfected by lentiviral vectors encoding second generation CARs composed of CD3ζ and 4-1BB. The second T-cell infusion was scheduled at least 1 month, and usually within 6 months after the first CAR-T treatment. Twenty-seven adult and pediatric patients, including 11 (41%) with extramedullary diseases (EMD), received the first CD19 CAR-T and 23 (85%) achieved CR. Subsequently, 21 out of 27 patients received the second CD22 CAR-T and were followed-up for a median of 19.7 (range, 5.6-27.3) months; 14 cases remained in CR, seven relapsed and two of them died from disease progression; Kaplan-Meier survival analysis showed overall survival and event-free survival rates of 88.5% and 67.5%, respectively, at both 12 months and 18 months. CAR-T associated graft-versus-host disease (GVHD) occurred in 23% of patients, with 8% new-onset acute GVHD and 15% persistent or worsened pre-existing cGVHD before CAR-T. This combination strategy of sequential CD19 and CD22 CAR-T therapy significantly improved the long-term survival in B-ALL patients who relapsed after transplantation.
- Published
- 2021
12. A Novel t(9;22;11) Translocation Variant Involving 11q23 in a Patient with Chronic Myeloid Leukemia
- Author
-
Yuehui, Lin, primary, Zheng, Qinglong, additional, Wu, Tong, additional, and LIU, DAN, additional
- Published
- 2020
- Full Text
- View/download PDF
13. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients
- Author
-
Chunrong Tong, Shuangyou Liu, Z L Deng, X J Zhao, P H Lu, Biping Deng, Tong Wu, Y N Wu, D P Lu, Alex H. Chang, Yuehui Lin, Yanlei Zhang, Xiang Zhang, Jing Pan, and J F Yang
- Subjects
Male ,0301 basic medicine ,Cancer Research ,T-Lymphocytes ,medicine.medical_treatment ,T-Cell Antigen Receptor Specificity ,Drug resistance ,Hematopoietic stem cell transplantation ,Immunotherapy, Adoptive ,Gastroenterology ,Cohort Studies ,Mice ,0302 clinical medicine ,Recurrence ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,Neoplasm ,Child ,Hematopoietic Stem Cell Transplantation ,Hematology ,Combined Modality Therapy ,Treatment Outcome ,Oncology ,Child, Preschool ,030220 oncology & carcinogenesis ,Heterografts ,Female ,Adult ,medicine.medical_specialty ,Adolescent ,Dose ,Antigens, CD19 ,Young Adult ,03 medical and health sciences ,Refractory ,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ,Internal medicine ,medicine ,Animals ,Humans ,B Acute Lymphoblastic Leukemia ,business.industry ,Immunotherapy ,medicine.disease ,Minimal residual disease ,Surgery ,Disease Models, Animal ,030104 developmental biology ,Drug Resistance, Neoplasm ,business - Abstract
Refractory or relapsed B lymphoblastic leukemia (B-ALL) patients have a dismal outcome with current therapy. We treated 42 primary refractory/hematological relapsed (R/R) and 9 refractory minimal residual disease by flow cytometry (FCM-MRD+) B-ALL patients with optimized second generation CD19-directed CAR-T cells. The CAR-T-cell infusion dosages were initially ranged from 0.05 to 14 × 105/kg and were eventually settled at 1 × 105/kg for the most recent 20 cases. 36/40 (90%) evaluated R/R patients achieved complete remission (CR) or CR with incomplete count recovery (CRi), and 9/9 (100%) FCM-MRD+ patients achieved MRD-. All of the most recent 20 patients achieved CR/CRi. Most cases only experienced mild to moderate CRS. 8/51 cases had seizures that were relieved by early intervention. Twenty three of twenty seven CR/CRi patients bridged to allogeneic hematopoietic stem cell transplantation (allo-HCT) remained in MRD- with a median follow-up time of 206 (45-427) days, whereas 9 of 18 CR/CRi patients without allo-HCT relapsed. Our results indicate that a low CAR-T-cell dosage of 1 × 105/kg, is effective and safe for treating refractory or relapsed B-ALL, and subsequent allo-HCT could further reduce the relapse rate.
- Published
- 2017
14. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
- Author
-
Jing, Pan, Qing, Niu, Biping, Deng, Shuangyou, Liu, Tong, Wu, Zhiyong, Gao, Zhaoli, Liu, Yue, Zhang, Xiaomin, Qu, Yanlei, Zhang, Shaohui, Liu, Zhuojun, Ling, Yuehui, Lin, Yongqiang, Zhao, Yanzhi, Song, Xiyou, Tan, Yan, Zhang, Zhihui, Li, Zhichao, Yin, Bingzhen, Chen, Xinjian, Yu, Ju, Yan, Qinlong, Zheng, Xuan, Zhou, Jin, Gao, Alex H, Chang, Xiaoming, Feng, and Chunrong, Tong
- Subjects
Adult ,Cytotoxicity, Immunologic ,Male ,Receptors, Chimeric Antigen ,Adolescent ,Biopsy ,Sialic Acid Binding Ig-like Lectin 2 ,T-Lymphocytes ,Receptors, Antigen, T-Cell ,Disease Management ,Infant ,Middle Aged ,Combined Modality Therapy ,Immunotherapy, Adoptive ,Young Adult ,Antigens, Neoplasm ,Child, Preschool ,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ,Cytokines ,Humans ,Female ,Child ,Follow-Up Studies - Abstract
Despite worldwide promising clinical outcome of CD19 CAR-T therapy, relapse after this therapy is associated with poor prognosis and has become an urgent problem to be solved. We conducted a CD22 CAR T-cell therapy in 34 relapsed or refractory (r/r) B-ALL pediatric and adult patients who failed from previous CD19 CAR T-cell therapy. Complete remission (CR) or CR with incomplete count recovery (CRi) was achieved in 24 of 30 patients (80%) that could be evaluated on day 30 after infusion, which accounted for 70.5% of all 34 enrolled patients. Most patients only experienced mild cytokine-release syndrome and neurotoxicity. Seven CR patients received no further treatment, and 3 of them remained in remission at 6, 6.6, and 14 months after infusion. Eleven CR patients were promptly bridged to transplantation, and 8 of them remained in remission at 4.6 to 13.3 months after transplantation, resulted in 1-year leukemia-free survival rate of 71.6% (95% CI, 44.2-99.0). CD22 antigen loss or mutation was not observed to be associated with relapsed patients. Our study demonstrated that our CD22 CAR T-cells was highly effective in inducing remission in r/r B-ALL patients, and also provided a precious window for subsequent transplantation to achieve durable remission.
- Published
- 2019
15. Relationship between stomatal density and the changes of atmospheric CO2 concentrations
- Author
-
Xinqiang, He, Yuehui, Lin, Jinxing, Lin, and Yuxi, Hu
- Published
- 1998
- Full Text
- View/download PDF
16. Corticosteroids Do Not Influence the Efficacy and Kinetics of CAR-T Cells for B-Cell Acute Lymphoblastic Leukemia
- Author
-
Chunrong Tong, Zhuojun Ling, Yanzhi Song, Yongqiang Zhao, Shuangyou Liu, Jing Pan, Tong Wu, Zhichao Yin, Biping Deng, Yuehui Lin, and Zhi-Yong Gao
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Immunology ,Biochemistry ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Medicine ,Dexamethasone ,business.industry ,Cell Biology ,Hematology ,medicine.disease ,Minimal residual disease ,Transplantation ,Cytokine release syndrome ,030104 developmental biology ,Graft-versus-host disease ,medicine.anatomical_structure ,Methylprednisolone ,Toxicity ,Bone marrow ,business ,030215 immunology ,medicine.drug - Abstract
Cytokine release syndrome (CRS) is the most prominent and potentially life-threatening toxicity caused by chimeric antigen receptor (CAR) T cell therapy, therefore, effectively controlling severe CRS is critical to ensure patient safety. Tocilizumab, an interleukin-6 receptor antagonist, has been widely used to treat CRS, whereas it is not clear if corticosteroids could be as another optimal choice for managing CRS. We applied corticosteroids instead of tocilizumab as the first-line agent to control CRS in patients with relapsed/refractory B-cell acute lymphoblastic leukemia during CAR-T therapy. The impacts of steroids on treatment efficiency and kinetics of CAR-T cells were assessed by comparing two groups of patients who did (42 cases) or did not (26 cases) receive steroids. Patients followed up less than one month (went to other hospitals for transplantation or died within one month) were excluded. Treatment effects were evaluated on day 30 after T-cell infusion and then monthly in follow-up patients. Minimal residual disease (MRD) was detected by multiparameter flow cytometry (FCM) and quantitative PCR for fusion genes. The dynamic monitoring of CAR-T cells was performed through flow cytometric quantitation of FITC+CD3+ T cells. B-cell aplasia (BCA) was assayed by FCM. Dexamethasone or methylprednisolone or both (alternately) were administrated. Dexamethasone was used in most cases especially for patients with neurologic symptoms; methylprednisolone was preferred for patients with pulmonary or liver dysfunction, and patients accepting high dose steroids. Steroids started with low dose and could be increased if symptoms were not resolved, for severe CRS, steroids would be escalated up to dexamethasone 20mg/m2/d or more higher up to methylprednisolone 10mg/kg/d. Once CRS was improved, steroids were rapidly reduced and stopped. A total of 68 patients (28 adults and 40 children younger than 18 years) were included, 22 (32.4%) presented with extramedullary diseases (EMD), bone marrow blasts in patients without EMD varied between 5%-96.5%, 31 (45.6%) patients had an allogeneic transplantation, 54 (79.4%) cases received CD19-specific and 14 (20.6%) received CD22-specific CAR-T therapy. Forty-two (61.8%) cases, including all (10) of grade III CRS, 68.2% (30/44) of grade II CRS and 2 patients with no CRS but with GVHD (1 case) or neurotoxicity (1 case), were administered steroids, among them, 23/42 (54.8%) received high dose steroids (>10mg/m2/d dexamethasone or equivalent), the duration of steroid use was 1-16 days (78.6% We found that there was no difference either in complete remission (CR) rate (95.2% vs 92.3%, p=.344) or in MRD negative CR rate (80.0% vs 79.2%, p=.249) between steroid and non-steroid group, verified that corticosteroids even high dose steroids did not influence the treatment response. Furthermore, we investigated the dynamics of CAR-T cells. Firstly, the expansion of CAR-T cells in peripheral blood (PB) was evaluated, the average CAR-T cell counts in steroid group were significantly higher than those in non-steroid group on D11 (p=.0302), D15 (p=.0053), D20 (p=.0045) and D30 (p=.0028), except for D7 when CAR-T cells began to expand (p=.9815), this demonstrated that steroids did not suppress the proliferation of CAR-T cells in PB. Secondly, the percentages of patients with detectable CAR-T cells in bone marrow (BM) and cerebrospinal fluid (CSF) were compared between steroid and non-steroid group, there were no differences both in BM (85.2% vs 78.6%, p=.923) and in CSF (68.6% vs 57.9%, p=.433), which implied steroids did not influence the trafficking of T-cells to BM and CSF. Thirdly, we monitored B-cell aplasia (BCA) in part of patients followed-up more than 2 months without further treatments, the percentages of patients with BCA in steroid group had no significant differences compared to non-steroid group at 2-month (p=.086) and 3-month (p=.146). Later, although limited cases left, in the steroid group, 100% of patients (4-month, 7/7; 5-month, 7/7; 6-month, 5/5) still maintained BCA and CR, indicating that corticosteroids did not impact the duration of functional CAR-T cells. In conclusion, corticosteroids do not compromise the treatment efficacy and kinetics of CAR-T cells, could be as a feasible and effective approach to manage CAR-T associated CRS. Disclosures No relevant conflicts of interest to declare.
- Published
- 2019
17. Leukemia Burden in Peripheral Blood Has Negative Impact on CD19-CART Cell Culture and Its Clinical Efficacy in Patients with Refractory or Relapsed B Cell Acute Lymphoblastic Leukemia
- Author
-
Alex Hong Chang, Yunlong Chen, Biping Deng, Chunrong Tong, Xuansha Niu, Yu 'e Zhang, Zhongxin Zhang, Jing Pan, Xiaoming Qu, Zhaoli Liu, Tong Wu, Shuangyou Liu, Ming Ma, and Yuehui Lin
- Subjects
Oncology ,medicine.medical_specialty ,Cyclophosphamide ,biology ,business.industry ,Immunology ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Peripheral blood mononuclear cell ,CD19 ,Chimeric antigen receptor ,Fludarabine ,Leukemia ,medicine.anatomical_structure ,immune system diseases ,Internal medicine ,Acute lymphocytic leukemia ,biology.protein ,Medicine ,Bone marrow ,business ,medicine.drug - Abstract
Introduction: Recently, chimeric antigen receptor (CAR) T-cell (CART) targeting CD19 has resulted in high complete remission (CR) rate in patients with refractory or relapsed B cell acute lymphoblastic leukemia (r/r B-ALL). Our previous clinical study has achieved more than 90% CR rate with CD19-CART in r/r B-ALL, but approximately 10% of patients have failed even CD19 high expression on their leukemia cells (Pan J, et al. Leukemia 2017; 31: 2587-2593). In current study, we investigate whether leukemia burden in peripheral blood (PB) has any influence in CART preparation ex vivo and its clinical efficacy. Patients and Methods: From June 2017 to June 2019, 143 r/r B-ALL patients received CD19-CART therapy. The median age was 8 years old (10 months to 65 years old). Thirty-six patients had leukemia cells in PB (positive group) and the median leukemia cells proportion after lymphocyte separation was 32.7% (3.23% to 83.2%); 107 patients had no leukemia cells detectable in PB (negative group). After apheresis, peripheral blood mononuclear cells (PBMCs) were isolated using lymphocyte separation liquid and leukemia cells proportion were determined by flow cytometry (FCM). PBMCs were activated with CD3 and CD28 antibodies for 24 hours, then transduced with the lentivirus encoding anti-CD19-CD3zeta-4-1BB CAR and cultured for 4-6 days in serum-free media containing IL2, IL7, IL15, IL21. Mycoplasma, endotoxin, bacteria and fungi were strictly controlled during the culture. Cell viability, expanding fold, percentage of CD3+ T cells, transduction efficiency and B cells were all examined before CART infusion. The patients received cyclophosphamide (250 mg/m2) and fludarabine (30 mg/m2) all for 3 days, and followed by CART infusion with a median number of 4.7 (0.6 to 43) X 105cells/kg. CD19-CART cells' expansion capacity in vivo was analyzed by FCM. Clinical efficacy was evaluated by bone marrow morphology and FCM on day 30. Results: Both normal B cells and leukemia B cells were all undetectable in infused CD19-CART. The median percentage of CD3+ T cells and transduction efficiency in positive and negative groups were 94.1% (80.3% to 98.0%) vs. 96.6% (80.1% to 99.5%) (P=0.056), and 35.6% (4.82% to 56.1%) vs. 52.4% (9.44% to 82%) (P Table Disclosures No relevant conflicts of interest to declare.
- Published
- 2019
18. Sequential CD19- and CD22-CART Cell Therapies for Relapsed B-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
- Author
-
Yuehui Lin, Zhi-Yong Gao, Yongqiang Zhao, Zhichao Yin, Shuangyou Liu, Yanzhi Song, Chunrong Tong, Jing Pan, Tong Wu, and Biping Deng
- Subjects
0301 basic medicine ,Cyclophosphamide ,medicine.medical_treatment ,Immunology ,Hematopoietic stem cell transplantation ,Biochemistry ,Cell therapy ,03 medical and health sciences ,0302 clinical medicine ,immune system diseases ,hemic and lymphatic diseases ,Acute lymphocytic leukemia ,medicine ,business.industry ,Cell Biology ,Hematology ,medicine.disease ,Chimeric antigen receptor ,Fludarabine ,Leukemia ,030104 developmental biology ,Graft-versus-host disease ,030220 oncology & carcinogenesis ,Cancer research ,business ,medicine.drug - Abstract
With traditional therapies, the prognosis of relapsed acute lymphoblastic leukemia (ALL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is extremely poor. Chimeric antigen receptor (CAR) T cell therapy targeting at CD19 has demonstrated a significant efficacy on refractory/relapsed (r/r) B-ALL, but single-target CART could not maintain a long-term remission. Recently, CD22-CART has also shown an exciting result in r/r B-ALL. Here we sequentially applied CD19- and CD22-specific CART cells to treat relapsed B-ALL post-HSCT and observed the therapeutic effect. From June 30,2017 through May 31,2018, twenty-four B-ALL patients (pts) relapsing after allo-HSCT with both antigens CD19 and CD22 expression on blasts were enrolled, the median age was 24 (2.3-55) years. Seventeen pts had hematologic relapse, 6 with both bone marrow and extramedullary (EM) involvements and 1 with EM disease (EMD) only. Fourteen pts had failed to previous therapies including chemotherapy, donor lymphocyte infusion, interferon and even murinized CD19-CART in other hospitals. Recipient-derived donor T cells were collected for producing CAR-T cells, which were transfected by a lentiviral vector encoding the CAR composed of CD3ζ and 4-1BB. Eighteen pts were initially infused with murinized CD19-CART, then humanized CD22-CART; while 6 pts (5 failed to prior murinized CD19-CART and 1 had bright CD22-expression) were initially infused with humanized CD22-CART, then humanized CD19-CART. The time interval between two infusions was 1.5-6 months based on patients' clinical conditions. The average dose of infused CAR T cells was 1.4×105/kg (0.4-9.2×105/kg) for CD19 and 1.9×105/kg (0.55-6.6×105/kg) for CD22. All patients received fludarabine with or without cyclophosphamide prior to each infusion, some pts accepted additional chemo drugs to reduce the disease burden. Treatment effects were evaluated on day 30 and then monthly after each CART, minimal residual disease (MRD) was detected by flow cytometry (FCM) and quantitative PCR for fusion genes, EMD was examined by PET-CT, CT or MRI. Sixteen patients finished sequential CD19- and CD22-CART therapies. Three cases could not undergo the second round of CART infusion (1 died, 1 gave up and 1 developed extensive chronic graft-versus-host disease (GVHD)). The rest of 5 pts are waiting for the second CART. After first T-cell infusion, 20/24 (83.3%) pts achieved complete remission (CR) or CR with incomplete count recovery (CRi), MRD-negative was 100% in CR or CRi pts, 3 (12.5%) cases with multiple EMD obtained partial remission (PR), and 1 (4.2%) died of severe cytokine release syndrome (CRS) and severe acute hepatic GVHD. Sixteen patients (15 CR and 1 PR) underwent the second CART therapy. Before second infusion, 3/15 pts in CR became MRD+ and others remained MRD-. On day 30 post-infusion, 1 of 3 MRD+ pts turned to MRD-, 1 maintained MRD+ ( BCR/ABL+) and 1 had no response then hematologic relapse later. The PR patient still had not obtained CR and then disease progressed. As of 31 May 2018, at a median follow-up of 6.5 (4-10) months, among 16 pts who received sequential CD-19 and CD-22 CART therapies, 1 had disease progression, 2 presented with hematological relapse and 2 with BCR/ABL+ only, the overall survival (OS) rate was 100% (16/16), disease-free survival (DFS) was 81.3% (13/16) and MRD-free survival was 68.8% (11/16). CRS occurred in 91.7% (22/24) pts in the first round of T-cell infusion, most of them were mild-moderate (grade I-II), merely 2 pts experienced severe CRS (grade III-IV). The second CART only caused grade I or no CRS since the leukemia burden was very low. GVHD induced by CART therapy was a major adverse event in these post-HSCT patients. After the first CART, 7/24 (29.2%) pts experienced GVHD, of them, 4 presented with mild skin GVHD, 2 with severe hepatic GVHD (1 recovered and 1 died), and 1 developed extensive chronic GVHD. No severe GVHD occurred in the second infusion. Our preliminary clinical study showed that for B-ALL patients who relapsed after allo-HSCT, single CD19- or CD22- CART infusion resulted in a high CR rate of 83.3%, sequentially combined CD19- and CD22-CART therapies significantly improved treatment outcome with the rate of OS, DFS and MRD-free survival being 100%, 81.3% and 68.8%, respectively, at a median follow-up of 6.5 months. The effect of CART on multiple EMD was not good and CART induced GVHD needs to be cautious. Disclosures No relevant conflicts of interest to declare.
- Published
- 2018
19. Clinical Implications of Germline Predisposition Gene Variants in Patients with Refractory or Relapsed B Acute Lymphoblastic Leukemia
- Author
-
Defeng, Zhao, Wu, Tong, Tong, Chunrong, Yuehui, Lin, and Zheng, Qinlong
- Abstract
Objectives:Gene variants are important factors in prognosis of the patients with hematological malignancies. In current study, our team investigate the relationship between blood and immune system germline predisposition variants and refractory/relapsed acute B lymphoblastic leukemia in patients.
- Published
- 2023
- Full Text
- View/download PDF
20. Safety and Efficacy of Low Dose CD19 Targeted Chimeric Antigen Receptor T (CAR-T) Cell Immunotherapy in 47 Cases with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Author
-
Zhaoli Liu, Tong Wu, Biping Deng, Peihua Lu, Chunrong Tong, Junfang Yang, Xian Zhang, Yanan Wu, Jing Pan, Alex H. Chang, Yuehui Lin, Yu’e Zhang, and Zhenling Deng
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Cyclophosphamide ,medicine.medical_treatment ,Immunology ,Hematopoietic stem cell transplantation ,Gene mutation ,Biochemistry ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Cytopenia ,Chemotherapy ,business.industry ,Cell Biology ,Hematology ,medicine.disease ,Chemotherapy regimen ,Fludarabine ,Surgery ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Bone marrow ,business ,medicine.drug - Abstract
Abstract Introduction: Patients (pts) with relapsed refractory B-ALL are mostly incurable by chemotherapy. The disease free survival (DFS) is low even treatment with allogeneic hematopoietic stem cell transplantation (allo-HSCT). We explored treatment of 47 cases of relapsed refractory B-ALL with low dose CD19 CAR-T cells and assessed the clinical safety and efficacy. Patients and Methods: (6-8)X107 pts' peripheral blood mononuclear cells(PBMCs) were activated with CD3 and CD28 antibodies for 24h, then transduced with the lentivirus encoding anti-CD19-CD3zeta-4-1BB CAR (Image1/Picture1) and cultured for 5-6 days in serum-free media containing IL2,IL7,IL15,IL21. All pts except one who had persistent cytopenia received cyclophosphamide 250 mg/m2/d X 3d, and fludarabine 30 mg/m2/d X 3d, then CAR-T cell infusion. Between Jul.31 2015 and Jul. 15 2016, a total of 47 cases were treated with CAR-T cells (Chart1). 37/47 cases had frank hematologically relapsed refractory B-ALL, who could not achieve complete remission (CR) after more than 1 cycles of chemotherapy. The median prior chemotherapy duration was 18 months. The median pre-treatment bone marrow blast percentage was 67% (6.5-98.5%). The most recently treated 15 cases had their PB blasts Chart 1: Characteristics of Patients Pre-CAR-T Image 1/Picture 1: Results: The pts received a median of 10 (0.5-140) X104cells/kg CAR-T cells, and the most recently treated 15 cases all received 10 X 104cells/kg. The median observation period was 201 days (20-368 days). On day 16-20 after CAR-T infusion, 31/35 (88.6%) relapsed hematological refractory cases achieved CR or incomplete CR(Cri), and 29/35 cases (82.9%) achieved negative MRD by FCM(CMR: complete molecular remission). No extramedullary leukemia was detected in any cases with residual disease. The most recently treated 15 consecutive cases all achieved CR with only mild ( Conclusion: Our anti-CD19 CAR-T cell therapy can result in a high CR/CRi /CMR rate in pts with refractory B-ALL and could overcome pre-existing risk factors for poor outcomes, including complex chromosome abnormalities, poor gene mutations, inherited predisposing gene mutation, extramedullary leukemia etc. Pts could be safely bridged into allo-HSCT for potential cure. The dose of infused CAR-T cells in our patients was far lower than previously reported in the literature and the culture period was only 6-7 days, which could dramatically reduce the cost of the CAR-T therapy. 10X104cells/kg of CAR-T cells was a safe and effective number for treating B-ALL. The major complication was CRS and the severity of CRS was directly correlated with the number of malignant B cells in the PB. The efficacy of CAR-T therapy was correlated to the infused number of CAR-T cells. The most recently treated 15 consecutive cases all achieved CR without severe CRS suggesting that the optimal number of CAR-T cells and patient selection are important for the efficacy and safety. Table. Table. Figure. Figure. Disclosures No relevant conflicts of interest to declare.
- Published
- 2016
21. Germline cytotoxic lymphocytes defective mutations in Chinese patients with lymphoma.
- Author
-
XUE CHEN, YANG ZHANG, FANG WANG, MANGJU WANG, WEN TENG, YUEHUI LIN, XIANGPING HAN, FANGYUAN JIN, Yuanli Xu, PANXIANG CAO, JIANCHENG FANG, PING ZHU, CHUNRONG TONG, and HONGXING LIU
- Subjects
GERM cells ,GENETIC mutation ,LYMPHOCYTES ,HEALTH of Chinese people ,LYMPHOMAS ,PERFORINS - Abstract
Certain patients with lymphoma may harbor mutations in perforin 1 (PRF1), unc-13 homolog D (UNC13D), syntaxin 11 (STX11), STXBP2 (syntaxin binding protein 2) or SH2 domain containing 1A (SH2D1A), which causes functional defects of cytotoxic lymphocytes. Data regarding the association between genetic defects and the development of lymphoma in Chinese patients are limited to date. In the present study, 90 patients with lymphoma were analyzed for UNC13D, PRF1, STXBP2, STX11, SH2D1A and X-linked inhibitor of apoptosis. Mutations were observed in 24 (26.67%) patients; 16 patients exhibited mutations in UNC13D, 7 exhibited PRF1 mutations, and 1 exhibited monoallelic mutation in STX11. UNC13D c.2588G>A/p.G863D mutation was detected in 9 patients (10.00%) and in 4/210 controls (1.90%). This mutation was predicted to be pathogenic and it predominantly existed in the Chinese population. These findings suggest that impaired cytotoxic machinery may represent a predisposing factor for the development of lymphoma. Furthermore, these data describe a distinct mutation spectrum in Chinese patients with lymphoma, whereby UNC13D is the most frequently mutated gene. In addition, these findings suggest UNC13D c.2588G>A mutation is a founder mutation in Chinese patients. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
22. UNC13D G863D as a genetic predisposition factor of lymphoma and a founder mutation in Chinese
- Author
-
Chunrong Tong, Xue Chen, Wen Teng, Yuanli Xu, Yuehui Lin, Yang Zhang, Xiangping Han, Fang Wang, and Hongxing Liu
- Subjects
Genetics ,Cancer Research ,business.industry ,medicine.disease ,Lymphoma ,Oncology ,STX11 ,medicine ,Genetic predisposition ,Cytotoxic T cell ,UNC13D ,business ,Founder mutation ,Function (biology) - Abstract
e19015Background: Some lymphoma patients may harbor mutations in PRF1, UNC13D, STX11, STXBP2 or SH2D1A, which cause function defects of cytotoxic lymphocytes. Data of the association between geneti...
- Published
- 2016
23. Mutaome Profiling and Retrospective Mutaome Profiling Using Archived Bone Marrow Smear In AML
- Author
-
Yuehui Lin, Hongxing Liu, Ping Zhu, Chunrong Tong, Junfang Yang, Xian Zhang, Fang Wang, Wen Teng, Qing Yin, and Xue Chen
- Subjects
Oncology ,Sanger sequencing ,NPM1 ,medicine.medical_specialty ,Pathology ,business.industry ,Bone Marrow Smear ,medicine.medical_treatment ,Immunology ,Cell Biology ,Hematology ,Gene mutation ,Biochemistry ,Targeted therapy ,symbols.namesake ,medicine.anatomical_structure ,Internal medicine ,CEBPA ,medicine ,symbols ,Clinical significance ,Bone marrow ,business - Abstract
Background Acute myeloid leukemia (AML) is a heterogeneous disease with respect to presentation and clinical outcome. In recent years, more and more somatic mutations and their clinical significance were identified in AML. Most AML patients carry multiple gene mutations and the repertoire of mutations changing during the disease process, which determine the patient's unique clinical manifestations. Herein we recommend using the novel word ”mutaome¡± for representing the repertoire of somatic gene mutations in a specific tumor tissue, and aimed to establish a panel of mutation profiling protocol and retrospective profiling using archived bone marrow smear for clinical use in AML. Methods and Cases Mutation profiling protocol for CEBPA, DNMT3A, FLT3-ITD/TKD, IDH1, IDH2, KIT, NPM1, PHF6 and TET2 by PCR and Sanger sequencing was established, with the detection sensitivity about 15% to 20%. Bone Marrow (BM) or peripheral blood (PB) was collected form patients with newly diagnosed or relapsed. Archived BM smear on glass slides at the time of newly diagnosed were used for retrospective mutation analysis. Results 1) Totally 61 archived smear, 106 fresh BM or PB and 2 paraffin-embedded pathological specimens from 157 patients were analyzed. Age ranged from 1 to 77 years old, with the median age of 27 years old. 2) 60.4% (102/169) samples carrying at least one mutation, 51.0% (53/102) of them carrying 2 or more mutations, 30.4% (31/102) carrying mutations within 2 or more different genes. The number of mutated sample for each gene is 33 for CEBPA¡¢9 DNMT3A¡¢35 FLT3¡¢6 IDH1¡¢7 IDH2¡¢7 KIT¡¢19 NPM1¡¢8 PHF6¡¢and 21 TET2. 3) Paired archived smear and relapsed samples were analyzed for 11 cases, 9 of them showing difference, detailed results shown in Table 1. 4) Totally 53 patients come to our hospital after certain treatment, with the tumor cells below 15% and without AML gene mutation results. For these patients, archived BM smear samples were used for retrospective mutation profiling and then to guide targeted therapy and stratified evaluation. Conclusions Panel testing for gene mutations is effective method for detection of AML molecular markers. For the patients came with partial remission and without gene mutation result, archived bone marrow smear sample can be used for retrospective mutation analysis and then help guiding targeted therapy and stratified evaluation. Disclosures: No relevant conflicts of interest to declare.
- Published
- 2013
24. Predictable Recurrence by Regular Monitoring Minimal Residual Disease with Flowcytometry In the Patients with Both AML and ALL: A Single-Center Study of 158 Cases
- Author
-
Chunrong Tong, Junfang Yang, Xian Zhang, Hui Wang, Jiangying Gu, Jie Zhao, Tong Wu, Dao-Pei Lu, Yuehui Lin, and Xinhong Fei
- Subjects
Oncology ,medicine.medical_specialty ,Chemotherapy ,Pediatrics ,Acute leukemia ,business.industry ,medicine.medical_treatment ,Immunology ,Cell Biology ,Hematology ,medicine.disease ,Single Center ,Biochemistry ,Chemotherapy regimen ,Minimal residual disease ,body regions ,Leukemia ,medicine.anatomical_structure ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Bone marrow ,Stage (cooking) ,business - Abstract
Abstract 1661 Minimal residual disease (MRD) is the most important factor to predict the prognosis after chemotherapy in the patients with acute leukemia(AL). Among the techniques for MRD detection, flowcytometry (FCM) is both sensitive and feasible tool, which can be used in almost all patients no matter with or without cytogenetic or molecular marker. It has been widely recognized that the MRD by FCM can predict the prognosis of the patients with ALL after several cycles of chemotherapy, but there are few reports on the value of MRD by FCM in AML. To investigate the clinical prognostic value of monitoring MRD regularly with FCM, the correlation of MRD and leukemia-free survival (LFS) in patients with AL without initial high risk factors was studied. From April 2005 to July 2009, 119 newly diagnosed patients (AML 85, ALL 34) and 39 treated cases (AML 19, ALL 20) were included. Those treated patients had attained the first complete remission (CR1) for more than 1 year after chemotherapy in other hospital and then were transferred to our hospital and detected MRD by FCM regularly since then. MRD in bone marrow (BM) was detected every 1 to 3 months in the first year after CR1, and every 2 to 6 months thereafter until hematological or extramedullary relapse or by July 2010. The special antibody combinations were employed for each patient according to aberrant expression of leukemia cells detected by the primary immune phenotype, or antigen drift in the follow-up. MRD was analyzed by the same doctor and assessed according to some abnormal characteristics, including antigen over-expression, antigen low-expression or even loss, co-expression of different lineages or different stage antigens on a single cell, and abnormal patterns in light scatters. MRD+ was defined as the aberrant cells more than 0.01% in BM at the twelfth month for AML and the fifth month for ALL. Among 85 newly diagnosed AML, 33 cases were MRD+ with the median ages 29(4-73)years old, 52 cases were MRD- with the median ages 35(9-68)years old. A total of 2/33 patients in MRD+ group and 40/52 patients in MRD- group remained in LFS. The probability of LFS at 12 months and 24 months was 56% and 16% in MRD+ group, 100% and 84% in MRD- group, respectively (see Figure 1), the difference between MRD+ and MRD- groups was significant statistically (p Disclosures: No relevant conflicts of interest to declare.
- Published
- 2010
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.